Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and 3BP today announced the first patient has been dosed in a Phase I/II study for the first-in-class radionuclide 177 Lu-IPN01087 (formerly known as 3BP-227). IPN01087 is a compound that targets cancer cells in patients with advan...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has approved Cabometyx ® (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval al...
Although Lexicon Pharmaceuticals ( LXRX ) has done what many biotechs fail to do, getting a drug through the clinical trial and FDA approval processes and onto the market, the commercialization of Xermelo really hasn’t helped the company or the stock, as the shares are quite a bit low...
Ipsen to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15, 2018 Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event Canada NewsWire PARIS, Nov. 8, 2018 PARIS , Nov....
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 14th and 15th, 2018 Canada NewsWire NEW YORK, Nov. 6, 2018 NEW YORK , Nov. 6, 2018 /CNW/ -- Deutsche Bank today announced the lineup for its Deposi...
If you want to have a better performance than the crowd, you must do things differently from the crowd. - Value Investor (Sir John Templeton) Amid the bear market that is hitting bioscience stocks lately, we strongly believe that investors should increase their research due diligence and...
Ipsen S.A. ADR ( OTCPK:IPSEY ): Q3 Revenue of $555.9M (+18.3% Y/Y) Press Release More news on: Ipsen S.A. ADR, Ipsen S.A., Earnings news and commentary, Healthcare stocks news,
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2018. Financial highlights Q3 2018 Group sales growth of 20.2% 1 driven by Specialty Care sales growth of 24.2% 1 reflecti...
– Patients in a real-world setting experienced similar dosing patterns as seen in the pivotal Phase 3 NAPOLI-1 clinical trial – Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced results from a retrospective, observational anal...
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...